Royalty Pharma Plc 8-K Summary: 2026 Annual General Meeting
Business Context and Reporting Period
This Form 8-K reports the results of the 2026 Annual General Meeting of Shareholders held on June 4, 2026. Royalty Pharma Plc, incorporated in England and Wales, presented 10 proposals to shareholders. A quorum was established with 508,180,103 shares (88.08% of combined voting power) present or represented by proxy.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on shareholder voting outcomes and corporate governance matters.
Material Changes and Voting Results
All 10 proposals submitted to shareholders were approved. Key voting outcomes include:
- Director Elections (Proposal 1): All nine nominees were elected. Notable vote splits included Vlad Coric, M.D., who received 54,472,087 votes against, and Pablo Legorreta, who received 29,448,236 votes against. Other nominees received significantly fewer "against" votes.
- Executive Compensation (Proposal 2): The non-binding advisory vote on named executive officer compensation passed with 476,044,602 votes for and 11,067,486 against.
- Auditor Ratification (Proposals 3 & 6): Ernst & Young LLP was ratified as the independent registered public accounting firm and re-appointed as the U.K. statutory auditor with overwhelming support.
- Share Authorization (Proposals 8, 9, & 10): Shareholders approved the share repurchase program, general share allotment authority, and the authority to allot shares without pre-emption rights. Proposal 10 (allotment without pre-emption) received the highest opposition with 42,016,406 votes against.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, or contingencies. The document serves as a record of the meeting's procedural outcomes.
Investor Verification Checklist
- Verify the specific terms of the share repurchase program authorized under Proposal 8.
- Review the definitive proxy statement filed on April 10, 2026, for detailed biographies of the elected directors and the rationale behind the "against" votes for specific nominees.
- Confirm the scope and limitations of the share allotment authority granted under Proposals 9 and 10.
- Check subsequent filings for the U.K. Annual Report and Accounts referenced in Proposal 4.